Revance Therapeutics Inc. (RVNC)
NASDAQ: RVNC
· Real-Time Price · USD
3.65
0.00 (0.00%)
At close: Feb 05, 2025, 3:59 PM
Revance Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|
| Development Services Revenue | 7.1M | 5.7M | 2M | 400K | 3.7M |
| Development Services Revenue Growth | +24.56% | +185.00% | +400.00% | -89.19% | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 62.22M | 65.42M | 67.48M | 84.3M | 67.73M | 77.38M | 66.01M | 65.24M | 64.74M | 46.83M | 43.94M | 45.2M | 51.77M | 49.68M | 48.07M | 55.82M | 48.18M | 29.61M | 21.22M | 18.77M | 16.74M | 13.6M | 12.91M | 13.36M | 14.15M | 12.73M | 13.62M | 11.89M | 9.15M | 8.61M | 7.75M | 7.1M | 7.5M | 7.02M | 7.46M | 6.91M | 5.83M | 6.36M | 6M |
| Selling, General, and Administrative Revenue Growth | -4.89% | -3.06% | -19.95% | +24.46% | -12.48% | +17.23% | +1.19% | +0.77% | +38.24% | +6.57% | -2.80% | -12.68% | +4.21% | +3.34% | -13.88% | +15.85% | +62.75% | +39.49% | +13.10% | +12.11% | +23.12% | +5.31% | -3.35% | -5.63% | +11.16% | -6.48% | +14.55% | +29.94% | +6.26% | +11.03% | +9.21% | -5.36% | +6.90% | -5.86% | +7.97% | +18.50% | -8.38% | +6.07% | n/a |
| Research and Development Revenue | 11.38M | 15.48M | 13.63M | 19.72M | 13.06M | 22.81M | 23.18M | 19.54M | 26.1M | 24.91M | 30.73M | 29.47M | 30.09M | 29.44M | 27.25M | 26.78M | 29.13M | 27.1M | 39.79M | 27.49M | 25.85M | 25.53M | 24M | 25.53M | 21.85M | 22.87M | 22.24M | 21M | 21.64M | 18.31M | 19.41M | 12.53M | 10.3M | 15.19M | 12.36M | 14.96M | 13.02M | 10.3M | 9.25M |
| Research and Development Revenue Growth | -26.51% | +13.63% | -30.90% | +51.00% | -42.74% | -1.60% | +18.61% | -25.14% | +4.78% | -18.93% | +4.28% | -2.08% | +2.22% | +8.04% | +1.75% | -8.06% | +7.48% | -31.89% | +44.74% | +6.37% | +1.26% | +6.38% | -6.02% | +16.86% | -4.47% | +2.84% | +5.88% | -2.95% | +18.22% | -5.68% | +54.90% | +21.70% | -32.23% | +22.87% | -17.33% | +14.90% | +26.33% | +11.34% | n/a |